Innovata Biomed in Japanese drug delivery deal:
This article was originally published in Clinica
Innovata Biomed (IB), the respiratory drug delivery subsidiary of Warrington, UK-based ML Laboratories, has signed an agreement with Japanese healthcare company Otsuka Pharmaceutical Co. Under the terms of the agreement, the Tokyo-based company has been given an exclusive licence to market its asthma treatment product, Meptin, in IB's "Clickhaler" dry powder inhaler in Japan and Spain. In return, IB will receive milestone payments and will supply the inhalers to Otsuka. "We strongly believe that this combinations will provide asthma patients with the most reliable, easy-to-use solution," said Otsuka's operations officer Masuhiro Yoshitake. Paul Bellington, managing director of St. Albans-based IB, added: "Today's announcement supports Innovata Biomed's position as one of the leading independent providers of respiratory drug delivery technologies to the pharmaceuticals industry."
You may also be interested in...
Data show Opdivo/Cabometyx combo bests Sutent for overall and progression-free survival and response endpoints in first-line RCC. Exelixis CEO says comparison to Sutent is standard control and allows better comparison to other combo regimens.
ES: Public Company Edition: Fifty biopharma companies launched initial public offerings in the US last year and there have been 52 so far in 2020, including Metacrine, Dyne, Athira and COMPASS.
In an update to stakeholders, the US FDA says regulators can successfully evaluate a firm’s performance, allowing it to eventually get medical software to market in the agency’s Pre-Cert Program.